Descrizione del progetto
Rete di formazione di successo fa il bis e affina nuovi obiettivi per le terapie del cancro
Le proteine sono onnipresenti ma non sono tutte uguali. I recettori accoppiati alle proteine G (GPCR) sono le proteine più grandi e più diverse presenti nel genoma dei mammiferi. Sono una classe di proteine transmembrana che trasducono stimoli o messaggeri extracellulari in segnali intracellulari attraverso l’interazione dei loro domini intracellulari con le proteine G. I recettori per le chemochine CXCR4 e ACKR3 sono GPCR che legano la chemochina CXCL12 e sono stati implicati nel cancro, nelle malattie infiammatorie e in quelle autoimmuni. Essi rappresentano uno dei principali obiettivi di numerosi tentativi di scoperta di farmaci, ma i loro meccanismi e ruoli esatti rimangono ancora poco chiari. L’iniziativa ONCORENET2.0 prevede di scoprire di più e indirizzare nuove terapie grazie all’aiuto di 15 ricercatori all’inizio della carriera e il recente lavoro pionieristico nel campo dei GPCR.
Obiettivo
Cancer is a major health burden responsible for 20% of European deaths. There is a critical need to understand its fundamental biological mechanisms. G protein-coupled receptors (GPCRs) are cell surface proteins which play an important role in regulating cellular functions integral to cancer biology and, as highly druggable proteins, oncogenic GPCRs are important therapeutic targets. ONCORNET2.0 builds on the success of ONCORNET (Oncogenic GPCR Network of Excellence and Training), a first-in-kind ETN in GPCR drug discovery that has successfully delivered scientific advance and training to talented early stage researchers (ESRs). ONCORNET2.0 will incorporate recent scientific and technological advances to understand and target two oncogenic GPCRs; the chemokine receptors CXCR4 and ACKR3. These are highly expressed in multiple tumours but their role in cancer progression remains poorly understood. We will develop new strategies for CXCR4/ACKR3 modulation (photochemistry, nanobodies) and investigate their effects on oncogenic responses, to yield key new knowledge and potential leads for drug development and commercialisation. ONCORNET2.0 will bring together the leading GPCR research groups in Europe and 15 ESRs. By leveraging on the success and experience of ONCORNET and recent ground-breaking advances in the field of GPCRs (e.g. cryo-EM, CRISPR-Cas, advanced microscopy), ONCORNET2.0 brings a young, gender-balanced team of PIs to target oncogenic GPCRs. The consortium will offer an extensive multidisciplinary training programme for ESRs ensuring their successful incorporation in today’s fast-moving drug development programmes. This programme integrates both research and transferable skill sets through blended learning. Our aim is that, through training these ESRs with interdisciplinary and intersectoral exposure, we will develop the next generation of scientists with skills that are in high demand by the drug development industries but rarely offered academically.
Campo scientifico
CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP.
CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP.
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural scienceschemical sciencesphysical chemistryphotochemistry
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- natural sciencesphysical sciencesopticsmicroscopy
- medical and health sciencesclinical medicineoncology
Programma(i)
Argomento(i)
Meccanismo di finanziamento
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Coordinatore
1081 HV Amsterdam
Paesi Bassi